Stock Titan·58 signal
Cash isn't expected to last a year as losses widen at Revelation Biosciences (REVB).Revelation Biosciences (REVB) reported a widening net loss of $9.65 million for the nine months ended September 30, 2026, compared to $6.40 million in the same period last year. The company's cash and cash equivalents of $9.12 million are not expected to sustain operations for another year, raising substantial doubt about its ability to continue as a going concern. Revelation Biosciences plans to seek additional equity or debt financing to support its clinical-stage drug development programs for acute and chronic kidney disease.
Original source